Literature DB >> 1380689

Genotype/phenotype association in cystic fibrosis: analyses of the delta F508, R553X, and 3905insT mutations.

S Liechti-Gallati1, I Bonsall, N Malik, V Schneider, L G Kraemer, A Ruedeberg, H Moser, R Kraemer.   

Abstract

A striking clinical phenomenon of cystic fibrosis is the heterogeneous disease expression. It must therefore be assumed that the nature of the mutations associated with cystic fibrosis might partly determine the phenotypic manifestations. The relation between the cystic fibrosis mutations delta F508, R553X, and 3905insT and clinical parameters such as sweat test electrolytes, age at chronic Pseudomonas aeruginosa colonization, Chrispin-Norman x-ray scores, and relative underweight have been investigated in 45 patients homozygous for delta F508 (delta F2), in 12 compound heterozygotes for delta F508/R553X (delta F1/RX1), in three R553X homozygotes (RX2), and in 13 patients compound heterozygous for delta F508/3905insT (delta F16). We have found significant differences between the genetically defined subgroups concerning the mean age at onset and the cumulative incidence of chronic P. aeruginosa colonization and Chrispin-Norman x-ray scores. The significant results as well as some trends regarding the relative underweight demonstrate a milder clinical course in R553X heterozygotes and more severe disease in the delta F16 group compared to delta F508 homozygotes. The three patients homozygous for R553X presented with a two-stage course showing mild progression before P. aeruginosa infection and as severe a course as the delta F16 patients after P. aeruginosa colonization at the age of 12 y. The findings presented here indicate that specific mutations can influence the severity and progression of the disease, implicating the importance of mutation and haplotype analyses. However, wide variations within the genetically homogeneous subgroups illustrate that other determinants of the clinical status do exist.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380689     DOI: 10.1203/00006450-199208000-00010

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

Authors:  R B Parad; C J Gerard; D Zurakowski; D P Nichols; G B Pier
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis--prognostic significance.

Authors:  C Aebi; R Bracher; S Liechti-Gallati; H Tschäppeler; A Rüdeberg; R Kraemer
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

3.  The CFTR frameshift mutation 3905insT and its effect at transcript and protein level.

Authors:  Javier Sanz; Thomas von Känel; Mircea Schneider; Bernhard Steiner; André Schaller; Sabina Gallati
Journal:  Eur J Hum Genet       Date:  2009-09-02       Impact factor: 4.246

4.  Clinical characteristics of 16 cystic fibrosis patients with the missense mutation R334W, a pancreatic insufficiency mutation with variable age of onset and interfamilial clinical differences.

Authors:  X Estivill; L Ortigosa; J Pérez-Frias; J Dapena; J Ferrer; L Peña; L Peña; R Llevadot; J Giménez; V Nunes
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

5.  Mutation analysis in 600 French cystic fibrosis patients.

Authors:  F Chevalier-Porst; A M Bonardot; R Gilly; J P Chazalette; M Mathieu; D Bozon
Journal:  J Med Genet       Date:  1994-07       Impact factor: 6.318

6.  Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients.

Authors:  T Dörk; F Mekus; K Schmidt; J Bosshammer; R Fislage; T Heuer; V Dziadek; T Neumann; N Kälin; U Wulbrand
Journal:  Hum Genet       Date:  1994-11       Impact factor: 4.132

7.  Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis.

Authors:  Richard Kraemer; David N Baldwin; Roland A Ammann; Urs Frey; Sabina Gallati
Journal:  Respir Res       Date:  2006-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.